Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma

• Status: Completed
• Trial end date: 2017-09-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study:

Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced Glioblastoma Patients ;

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
• Collaborators: Beijing Shijitan Hospital; Beijing Shijitan Hospital, Capital Medical University

Criteria

Inclusion Criteria:

1. Patients with pathologic or/and FNAC confirmation of advanced glioblastoma(WHO,III-IV grade) but without effective treatment or with treatment failure;

2. Between 18 and 65 years of age, KPS≥40;

3. According to RANO(2010), the parents will be eligible if one of the following conditions apply: steroid dose increased or stable,the enhanced tumor lesion increased more than 25%; the unenhanced tumor lesion increased because of the progressive tumor,even if the lesion was unmeasurable.

4. Life expectancy of at least three (3) months at the enrollment;

5. Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:

1)PLT count≥100×10~9/L, 2)WLB count≥4.0×10~9/L and ≤12×10~9/L, 3)Neutrophil granulocyte count≥2.0×10~9/L, 4)HGB count≥90g/L, 5)Total bilirubin <=1.5 times of ULN, 6)ALT/AST ≤2.5 times of ULN, 7)SCr≤1.5 times of ULN, 8)Normal ECG with LVEF (≥50%) measured by echocardiography; 6.Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months; 7.Volunteered for the phase 1 trial and sign the informed consent without protest;

Exclusion Criteria:

1. Patients who have received large area radiotherapy （>30% marrow capacity）;

2. Without pathologic or/and FNAC confirmation of advanced glioblastoma;

3. Patients who has primary immunodeficiency diseases；

4. Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;

5. Patients who have received the therapy of chemotherapy or radical radiotherapy within 4 weeks before enrollment;

6. Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;

7. Patients who have received therapy of major surgery within 4 weeks or biopsy surgery within 2 weeks before enrollment;

8. Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;

9. Patients who have history of drug abuse;

10. Uncontrollable psychopaths；

11. Uncontrollable diabetes；

12. Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;

13. Patients who had received a therapy of another investigational drug within 12 weeks or patients who are still in another clinical trial at the enrollment;

14. Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;

15. Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;

16. Allergic to the investigational drug;

17. Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).

18. Patients who have received the therapy of adrenal steroid hormones within 1 week before enrollment or will receive the therapy for a long period time，except for Corticosteroid nasal spray，Inhaled Steroid and Topical steroids .